Literature DB >> 10487609

Regulation of expression of Na+,K+-ATPase in androgen-dependent and androgen-independent prostate cancer.

L J Blok1, G T Chang, M Steenbeek-Slotboom, W M van Weerden, H G Swarts, J J De Pont, G J van Steenbrugge, A O Brinkmann.   

Abstract

The beta 1-subunit of Na+,K+-ATPase was isolated and identified as an androgen down-regulated gene. Expression was observed at high levels in androgen-independent as compared to androgen-dependent (responsive) human prostate cancer cell lines and xenografts when grown in the presence of androgens. Down-regulation of the beta 1-subunit was initiated at concentrations between 0.01 nM and 0.03 nM of the synthetic androgen R1881 after relatively long incubation times (> 24 h). Using polyclonal antibodies, the concentration of beta 1-subunit protein, but not of the alpha 1-subunit protein, was markedly reduced in androgen-dependent human prostate cancer cells (LNCaP-FGC) cultured in the presence of androgens. In line with these observations it was found that the protein expression of total Na+,K+-ATPase in the membrane (measured by 3H-ouabain binding) was also markedly decreased. The main function of Na+,K+-ATPase is to maintain sodium and potassium homeostasis in animal cells. The resulting electrochemical gradient is facilitative for transport of several compounds over the cell membrane (for example cisplatin, a chemotherapeutic agent experimentally used in the treatment of hormone-refractory prostate cancer). Here we observed that a ouabain-induced decrease of Na+,K+-ATPase activity in LNCaP-FGC cells results in reduced sensitivity of these cells to cisplatin-treatment. Surprisingly, androgen-induced decrease of Na+,K+-ATPase expression, did not result in significant protection against the chemotherapeutic agent.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10487609      PMCID: PMC2374343          DOI: 10.1038/sj.bjc.6690647

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  26 in total

1.  Role of the Na+, K(+)-adenosine triphosphatase in the accumulation of cis-diamminedichloroplatinum(II) in human ovarian carcinoma cells.

Authors:  P A Andrews; S C Mann; H H Huynh; K D Albright
Journal:  Cancer Res       Date:  1991-07-15       Impact factor: 12.701

2.  Isolation of cDNAs that are differentially expressed between androgen-dependent and androgen-independent prostate carcinoma cells using differential display PCR.

Authors:  L J Blok; M V Kumar; D J Tindall
Journal:  Prostate       Date:  1995-04       Impact factor: 4.104

Review 3.  Metabotropic glutamate receptors in brain function and pathology.

Authors:  D D Schoepp; P J Conn
Journal:  Trends Pharmacol Sci       Date:  1993-01       Impact factor: 14.819

Review 4.  Understanding the sodium pump and its relevance to disease.

Authors:  A M Rose; R Valdes
Journal:  Clin Chem       Date:  1994-09       Impact factor: 8.327

5.  Differential Na+,K(+)-ATPase activity and cisplatin sensitivity between transformants induced by H-ras and those induced by K-ras.

Authors:  N Shinohara; Y Ogiso; T Arai; S Takami; K Nonomura; T Koyanagi; N Kuzumaki
Journal:  Int J Cancer       Date:  1994-09-01       Impact factor: 7.396

6.  Androgen induction of a human prostate-specific kallikrein, hKLK2: characterization of an androgen response element in the 5' promoter region of the gene.

Authors:  P Murtha; D J Tindall; C Y Young
Journal:  Biochemistry       Date:  1993-06-29       Impact factor: 3.162

7.  Ouabain-resistant non-small-cell lung-cancer cell line shows collateral sensitivity to cis-diamminedichloroplatinum(II) (CDDP).

Authors:  T Ohmori; K Nishio; S Ohta; N Kubota; M Adachi; K Komiya; N Saijo
Journal:  Int J Cancer       Date:  1994-04-01       Impact factor: 7.396

8.  LNCaP model of human prostatic carcinoma.

Authors:  J S Horoszewicz; S S Leong; E Kawinski; J P Karr; H Rosenthal; T M Chu; E A Mirand; G P Murphy
Journal:  Cancer Res       Date:  1983-04       Impact factor: 12.701

9.  Adjuvant therapy for localized prostate cancer.

Authors:  J D Schmidt; R P Gibbons; G P Murphy; A Bartolucci
Journal:  Cancer       Date:  1993-02-01       Impact factor: 6.860

Review 10.  Intermittent endocrine therapy and its potential for chemoprevention of prostate cancer.

Authors:  R T Oliver; C J Gallagher
Journal:  Cancer Surv       Date:  1995
View more
  15 in total

1.  Na,K-ATPase subunits as markers for epithelial-mesenchymal transition in cancer and fibrosis.

Authors:  Sigrid A Rajasekaran; Thu P Huynh; Daniel G Wolle; Cromwell E Espineda; Landon J Inge; Anna Skay; Charles Lassman; Susanne B Nicholas; Jeffrey F Harper; Anna E Reeves; Mansoor M Ahmed; James M Leatherman; James M Mullin; Ayyappan K Rajasekaran
Journal:  Mol Cancer Ther       Date:  2010-05-25       Impact factor: 6.261

2.  Novel role for Na,K-ATPase in phosphatidylinositol 3-kinase signaling and suppression of cell motility.

Authors:  Sonali P Barwe; Gopalakrishnapillai Anilkumar; Sun Y Moon; Yi Zheng; Julian P Whitelegge; Sigrid A Rajasekaran; Ayyappan K Rajasekaran
Journal:  Mol Biol Cell       Date:  2004-12-22       Impact factor: 4.138

Review 3.  Adapting mass spectrometry-based platforms for clinical proteomics applications: The capillary electrophoresis coupled mass spectrometry paradigm.

Authors:  Jochen Metzger; Peter B Luppa; David M Good; Harald Mischak
Journal:  Crit Rev Clin Lab Sci       Date:  2009       Impact factor: 6.250

4.  Discovery and validation of urinary biomarkers for prostate cancer.

Authors:  Dan Theodorescu; Eric Schiffer; Hartwig W Bauer; Friedrich Douwes; Frank Eichhorn; Reinhard Polley; Thomas Schmidt; Wolfgang Schöfer; Petra Zürbig; David M Good; Joshua J Coon; Harald Mischak
Journal:  Proteomics Clin Appl       Date:  2008-03-07       Impact factor: 3.494

Review 5.  Purinergic signaling and tumor microenvironment in cervical Cancer.

Authors:  Marta Schmidt Pfaffenzeller; Maria Luiza Mukai Franciosi; Andréia Machado Cardoso
Journal:  Purinergic Signal       Date:  2020-03-13       Impact factor: 3.765

Review 6.  [Capillary electrophoresis coupled to mass spectrometry for proteome analysis. An innovative diagnostic method for prostate and bladder cancer].

Authors:  S Wittke; E Schiffer; H W Bauer
Journal:  Urologe A       Date:  2007-07       Impact factor: 0.803

7.  Na, K-ATPase: Ubiquitous Multifunctional Transmembrane Protein and its Relevance to Various Pathophysiological Conditions.

Authors:  Mohd Suhail
Journal:  J Clin Med Res       Date:  2010-02-26

8.  Downregulation of intracellular nm23-H1 prevents cisplatin-induced DNA damage in oesophageal cancer cells: possible association with Na(+), K(+)-ATPase.

Authors:  N lizuka; K Miyamoto; A Tangoku; H Hayashi; S Hazama; S Yoshino; K Yoshimura; K Hirose; H Yoshida; M Oka
Journal:  Br J Cancer       Date:  2000-11       Impact factor: 7.640

9.  Gene expression profiles of human endometrial cancer samples using a cDNA-expression array technique: assessment of an analysis method.

Authors:  E Smid-Koopman; L J Blok; S Chadha-Ajwani; T J Helmerhorst; A O Brinkmann; F J Huikeshoven
Journal:  Br J Cancer       Date:  2000-07       Impact factor: 7.640

10.  Epithelial Na, K-ATPase expression is down-regulated in canine prostate cancer; a possible consequence of metabolic transformation in the process of prostate malignancy.

Authors:  Ali Mobasheri; Richard Fox; Iain Evans; Fay Cullingham; Pablo Martín-Vasallo; Christopher S Foster
Journal:  Cancer Cell Int       Date:  2003-06-13       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.